Table 1.
Comparison of clinicopathological characteristics of different HR+PLR groups.
| Variables | HR+PLR = 0, n (%) | HR+PLR = 1, n (%) | HR+PLR = 2, n (%) | P |
|---|---|---|---|---|
| Age | 0.049 | |||
| <60 | 28 (73.6) | 65 (52) | 76 (53.1) | |
| ≥60 | 10 (26.4) | 60 (48) | 67 (46.9) | |
| Gender | 0.787 | |||
| Male | 32 (84.2) | 100 (80) | 113 (79) | |
| Female | 6 (15.8) | 25 (20) | 30 (21) | |
| T stage | <0.001 | |||
| T4b | 10 (26.4) | 64 (51.2) | 88 (61.5) | |
| Not T4b | 20 (52.6) | 61 (48.8) | 55 (38.5) | |
| N stage | 0.017 | |||
| N0 or N1 or N2 | 19 (50) | 41 (32.8) | 50 (35) | |
| N3a or N3b | 19 (50) | 84 (67.2) | 93 (65) | |
| Number of liver metastases | 0.018 | |||
| Single | 15 (39.5) | 65 (52) | 50 (35) | |
| Multiple | 23 (60.5) | 60 (48) | 93 (65) | |
| Gastrectomy | <0.001 | |||
| Yes | 29 (76.3) | 74 (59.2) | 50 (35) | |
| No | 9 (23.7) | 51 (40.8) | 93 (35) | |
| Hepatectomy | 0.001 | |||
| Yes | 13 (34.3) | 45 (36) | 23 (16.1) | |
| No | 25 (65.7) | 80 (64) | 120 (83.9) | |
| Chemotherapy | 0.325 | |||
| Yes | 19 (50) | 61 (48.8) | 58 (40.6) | |
| No or unknown | 19 (50) | 64 (51.2) | 85 (59.4) | |
| Ascites | 0.127 | |||
| Yes | 12 (31.6) | 21 (16.8) | 33 (23.1) | |
| No | 26 (68.4) | 104 (83.2) | 110 (76.9) | |
| Peritoneal metastasis | 0.012 | |||
| Yes | 16 (34.3) | 21 (16.8) | 32 (22.4) | |
| No | 25 (65.7) | 104 (83.2) | 111 (77.6) | |
| PNI | 0.028 | |||
| ≤48.1 | 15 (39.5) | 50 (40) | 78 (54.5) | |
| >48.1 | 25 (60.5) | 75 (60) | 65 (45.5) | |
| NLR | 0.045 | |||
| ≤2.58 | 18 (47.4) | 66 (52.8) | 54 (37.8) | |
| >2.58 | 20 (52.6) | 59 (47.2) | 89 (62.2) |
HR: hemoglobin-to-red cell distribution width; PLR: platelet-lymphocyte ratio; PNI: prognostic nutritional index; NLR: neutrophil-lymphocyte ratio.